Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Feasibility of intensity-modulated and image-guided radiotherapy for locally advanced esophageal cancer

Authors: Nam P Nguyen, Siyoung Jang, Jacqueline Vock, Vincent Vinh-Hung, Alexander Chi, Paul Vos, Judith Pugh, Richard A Vo, Misty Ceizyk, Anand Desai, Lexie Smith-Raymond, the International Geriatric Radiotherapy Group

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

In this study the feasibility of intensity-modulated radiotherapy (IMRT) and tomotherapy-based image-guided radiotherapy (IGRT) for locally advanced esophageal cancer was assessed.

Methods

A retrospective study of ten patients with locally advanced esophageal cancer who underwent concurrent chemotherapy with IMRT (1) and IGRT (9) was conducted. The gross tumor volume was treated to a median dose of 70 Gy (62.4-75 Gy).

Results

At a median follow-up of 14 months (1-39 months), three patients developed local failures, six patients developed distant metastases, and complications occurred in two patients (1 tracheoesophageal fistula, 1 esophageal stricture requiring repeated dilatations). No patients developed grade 3-4 pneumonitis or cardiac complications.

Conclusions

IMRT and IGRT may be effective for the treatment of locally advanced esophageal cancer with acceptable complications.
Appendix
Available only for authorised users
Literature
1.
Pottgen C, Stuchske M: Radiotherapy versus surgery within multimodality protocols for esophageal cancer- a meta-analysis of the randomized trials. Cancer Treat Rev. 2012, 38: 599-604. 10.1016/j.ctrv.2011.10.005.CrossRefPubMed
2.
Van Hagen P, Hulsholf MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Winjhoven BPL, Richel DJ, Nieuwenhuijen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, ten Kate FJW, Creemers JG, Punt CJA, Plukker JTM, Verheul HMW, Spillenaar EJ, van Dekken H, van den Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Renders JG, Tilanus HW, van der Gast A, for the Cross group: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012, 366: 2074-2084. 10.1056/NEJMoa1112088.CrossRefPubMed
3.
Cooper JS, Guo MD, Herskovic A, McDonald JS, Martenson JA, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL: Chemoradiotherapy of locally advanced esophageal cancer: long term follow-up of a prospective randomized trial (RTOG 85-01). Radiotherapy oncology group. JAMA. 1999, 281: 1623-1627.CrossRefPubMed
4.
Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L, Emami B: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 1997, 15: 277-284.PubMed
5.
Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet T, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cell carcinoma of the esophagus. J Clin Oncol. 2005, 23: 2310-2317. 10.1200/JCO.2005.00.034.CrossRef
6.
Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Sieber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H: Chemoradiation with or without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005, 23: 2310-2317. 10.1200/JCO.2005.00.034.CrossRefPubMed
7.
Han J, Zhu W, Yu C, Zhou X, Li T, Zhang X: Clinical study of concurrent chemoradiotherapy or radiotherapy alone for esophageal cancer patients with positive lymph nodes metastasis. Tumori. 2012, 98: 60-65.PubMed
8.
Nutting CM, Bedford JL, Cosgrove VP, Tait DM, Dearnaley DP, Webb S: A comparison of conformal and intensity-modulated techniques for esophageal radiotherapy. Radiother Oncol. 2001, 61: 157-163. 10.1016/S0167-8140(01)00438-8.CrossRefPubMed
9.
Chandra A, Guerrero TM, Liu HH, Tucker SL, Liao Z, Wang X, Murshed H, Bonnen MD, Garg AK, Stevens CW, Chang JY, Jeter MD, Mohan R, Cox JD, Komaki R: Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol. 2005, 77: 247-253. 10.1016/j.radonc.2005.10.017.CrossRefPubMed
10.
Kole TP, Aghayere O, Kwah J, Yorke ED, Goodman KA: Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three dimensional conformal radiotherapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys. 2011, 83: 1580-1586.CrossRef
11.
Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z: Propensity score-based comparison of long-term outcomes with 3-D conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012, 84: 1078-1085. 10.1016/j.ijrobp.2012.02.015.CrossRefPubMedPubMedCentral
12.
Chen YJ, Liu A, Han C, Tsai PT, Schultheiss TE, Pezner RD, Vora N, Lim D, Shibata S, Kernstine KH, Wong JY: Helical tomotherapy for radiotherapy in esophageal cancer: a preferred plan with better conformal target coverage and more homogeneous dose distribution. Med Dosimetry. 2007, 32: 166-171. 10.1016/j.meddos.2006.12.003.CrossRef
13.
Nguyen NP, Krafft SP, Vinh-Hung V, Vos P, Almeida F, Jang S, Ceizyk M, Desai A, Davis R, Hamilton R, Modarresifar H, Abraham D, Smith-Raymond L: Feasibility of tomotherapy to reduce normal lung and cardiac toxicity for distal esophageal cancer compared to three-dimensional radiotherapy. Radiother Oncol. 2011, 101: 438-442. 10.1016/j.radonc.2011.07.015.CrossRefPubMed
14.
Chen WJ, Kerstine KH, Shibata H, Lim D, Smith DD, Tang M, Liu A, Pezner RD, Wong JYC: Image-guided radiotherapy of esophageal cancer by helical tomotherapy: acute toxicity and preliminary clinical outcome. J Thor Dis. 2009, 1: 11-16.
15.
Geler M, Astner ST, Duma MN, Jacob V, Nieder C, Putzhammer J, Winkler C, Molls M, Gelnitz H: Dose-escalated simultaneous integrated boost treatment of prostate cancer patients via helical tomotherapy. Strahlenther Onkol. 2012, 188: 410-416. 10.1007/s00066-012-0081-8.CrossRef
16.
Simone CB, Ly D, Dan TD, Ondos J, Ning H, Belard A, O’Connell J, Miller RW, Simone NL: Comparison of intensity-modulated radiotherapy, adaptive radiotherapy for soft tissue changes during helical tomotherapy for head and neck cancer. Radiother Oncol. 2011, 101: 376-382. 10.1016/j.radonc.2011.05.028.CrossRefPubMedPubMedCentral
17.
Duma MN, Kampfer S, Schuster T, Winkler C, Geinitz H: Adaptive radiotherapy for soft tissue changes during helical tomotherapy for head and neck cancer. Strahlenther Onkol. 2012, 188: 243-247. 10.1007/s00066-011-0041-8.CrossRefPubMed
18.
Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Havashi Y, Hofletter W, Komaki R, Liao Z, Ajani JA: Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012, 118: 2632-2640. 10.1002/cncr.26586.CrossRefPubMed
19.
Hart JP, McCurdy MR, Ezhil M, Wei W, Khan M, Luo D, Munden RF, Johnson VE, Guerrero TM: Radiation pneumonitis: correlation of toxicity with pulmonary metabolic radiation response. Int J Radiat Oncol Biol Phys. 2008, 71: 967-971. 10.1016/j.ijrobp.2008.04.002.CrossRefPubMedPubMedCentral
20.
Semrau R, Herzoz SL, Vallbomer D, Kocher M, Holscher A, Muller RP: Radiotherapy in elderly patients with inoperable esophageal cancer. Is there a benefit?. Strahlenther Onkol. 2012, 188: 226-234. 10.1007/s00066-011-0039-2.CrossRefPubMed
21.
Lee HK, Vaporciyan AA, Cox JD, Tucker SL, Putnan JB, Ajani JA, Liao Z, Swisher SG, Roth JA, Smythe WR, Walsh GL, Mohan R, Liu HH, Mooring D, Komaki R: Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys. 2003, 57: 1317-1322. 10.1016/S0360-3016(03)01373-7.CrossRefPubMed
22.
Kumekawa Y, Kanedo K, Ito H, Kurahashi T, Konishi K, Katagiri A, Yamamoto T, Kuwahara M, Kubota Y, Muramoto T, Mizutani Y, Imawari M: Late toxicity in complete responses cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Gastroenterol. 2006, 41: 425-432. 10.1007/s00535-006-1771-8.CrossRefPubMed
23.
Morota M, Gomi K, Kozuka T, Chin K, Matsuura M, Oquchi M, Ito H, Yamashita T: Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2009, 75: 122-128. 10.1016/j.ijrobp.2008.10.075.CrossRefPubMed
24.
La TH, Minn AY, Fisher GA, Ford JM, Kunz P, Goodman KA, Koong AC, Chang DT: Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. Dis Esophagus. 2010, 23: 300-308.CrossRefPubMed
25.
Nguyen NP, Krafft SP, Vos P, Vinh-Hung V, Ceizyk M, Jang S, Desai A, Abraham D, Ewell L, Watchman C, Hamilton R, Jo BH, Karlsson U, Smith-Raymond L: Feasibility of tomotherapy for graves’ opthalmopathy: Dosimetry comparison with conventional radiotherapy. Strahlenther Onkol. 2011, 187: 568-574. 10.1007/s00066-011-2220-z.CrossRefPubMed
26.
Nguyen NP, Vock J, Chi A, Vinh-Hung V, Dutta S, Ewell L, Jang S, Betz M, Almeida F, Miller M, Davis R, Sroka T, Vo RP, Karlsson U, Vos P: Impact of intensity-modulated and image-guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer. Strahlenth Onkol. 2012, 188: 677-683. 10.1007/s00066-012-0125-0.CrossRef
27.
Liu M, Shi X, Guo X, Yao W, Liu Y, Zhao K, Liang G: Long-term outcome of irradiation with or without chemotherapy for esophageal squamous cell carcinoma: a final report on a prospective trial. Radiat Oncol. 2012, 12: 142-CrossRef
28.
Toita T, Ogawa K, Adachi G, Kakinohana Y, Nishikoramori Y, Iraha S, Utsunomiya T, Murayama S: Concurrent chemoradiotherapy for squamous cell carcinoma of thoracic esophagus: feasibility and outcome of large regional field and high dose external beam boost radiation. Jpn J Clin Oncol. 2001, 31: 375-381. 10.1093/jjco/hye084.CrossRefPubMed
29.
Hurmuzlu M, Monge OR, Smaaland R, Viste A: High dose definitive concurrent chemoradiotherapy in non metastatic locally advanced esophageal carcinoma. Dis Esophagus. 2010, 23: 244-252. 10.1111/j.1442-2050.2009.00999.x.CrossRefPubMed
30.
Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva A, Cox JD, Komaki R: Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys. 2012, 82: 468-474. 10.1016/j.ijrobp.2010.10.023.CrossRefPubMed
31.
Zhu W, Zhou K, Yu C, Han J, Li T, Chen X: Efficacy analysis of simplified intensity-modulated radiotherapy with high or conventional dose and concurrent chemotherapy for patients with neck and upper thoracic esophageal carcinoma. Asian Pacific J Cancer Prev. 2012, 13: 803-807. 10.7314/APJCP.2012.13.3.803.CrossRef
32.
Fokas E, Weiss C, Rodel C: The role of radiotherapy in the multimodal management of esophageal cancer. Dig Dis. 2013, 31: 30-37. 10.1159/000347170.CrossRefPubMed
Metadata
Title
Feasibility of intensity-modulated and image-guided radiotherapy for locally advanced esophageal cancer
Authors
Nam P Nguyen
Siyoung Jang
Jacqueline Vock
Vincent Vinh-Hung
Alexander Chi
Paul Vos
Judith Pugh
Richard A Vo
Misty Ceizyk
Anand Desai
Lexie Smith-Raymond
the International Geriatric Radiotherapy Group
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-265

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

The nucleolar size is associated to the methylation status of ribosomal DNA in breast carcinomas

Research article

Does the time between CT scan and chemotherapy increase the risk of acute adverse reactions to iodinated contrast media in cancer patients?

Research article

Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patients

Research article

Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study

Research article

Elevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinoma

Study protocol

A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits